Oncoinvent, a clinical stage, radiopharmaceutical company developing innovative treatments for solid cancers, today announced that the first patient has been dosed in its Phase 2 study of Radspherin® in patients with peritoneal carcinomatosis from ovarian cancer. Radspherin® is a novel alpha-radiation therapy candidate designed for targeted, local treatment of cancers that have spread to body...